Embed Size (px)
Citation preview
Wockhardt Limited
Investor Presentation By
Dr. Murtaza Khorakiwala Managing Director
Q1FY16
Safe Harbor Statement
• Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “August”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions August constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to reflect events or circumstances after the date thereof.
Investor Presentation August 2015 2
Introduction to Wockhardt Key Business Dynamics
ROW operations Wockhardt Direct operations
USA
UK, Ireland, France, Switz.
India
Mexico
Wockhardt Today
Investor Presentation August 2015 4
Direct Operations
in India, USA
and Europe
Multi Ethnic workforce from
21 different Nationalities
UK Ireland
Wockhardt Today
Investor Presentation August 2015 5
12
Manufacturing Locations globally
Ankleshwar Daman (2 Plants)
Aurangabad (5 Plants)
Baddi
Chicago
Formulations APIs
9 sites in India
Wockhardt Today
Investor Presentation August 2015 6
3 R&D Centers
worldwide
USA / UK & India
Key Business Update
Key Business Update
Investor Presentation August 2015 8
US FDA has completed inspection in one of the manufacturing facility in Himachal Pradesh in July, 2015 and no 483 has been issued to the company.
US FDA’s inspection of Waluj facility completed during the quarter with minor observations.
The Company’s on going efforts towards compliance measures for Chikalthana and Waluj facilities continues to be in place.
Resumed Supplies to UK from our Chikalthana Facility.
Received the coveted Breakthrough discovery (QIDP) status for another NCE product WCK 4873 during the quarter. Previously 2 of its drug WCK 771 and WCK 2349 received QIDP status. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.
Got approval from US FDA for marketing 5mg/5ml of Oxycodone HCL liquid from MGP. Oxycodone is used extensively in management of pain, especially in opioid tolerant patients.
Filed for 54 patents during the quarter taking the cumulative filings to 2322 and has been granted 26 patents during the quarter taking the cumulative patents granted to 367.
Regulatory Update
Research Update
Q1FY16 Results
Sales – Growth of 15% over Q1FY15
Investor Presentation August 2015 10
Rs.crore
Growth of 15% in Q1FY16 over Q1FY15
EBITDA – Growth of 165% over Q1FY15
Investor Presentation August 2015 11
Rs.crore
Growth of 165% in Q1FY16 over Q1FY15
PAT – Growth of 470% over Q1FY15
Investor Presentation August 2015 12
Rs.crore
Growth of 470% in Q1FY16 over Q1FY15
Research – 13.3% of Sales in Q1FY16
Investor Presentation August 2015 13
Growth of 31% in Q1FY16 over Q1FY15
US Business
Investor Presentation August 2015 14
• Contributes 20% of Total Revenue.
• Declines by 21% (26% in $ terms)
over Q1FY15.
• During the Q1FY16, 5 ANDA’s filed
& 1 approval received cumulative
ANDA’s pending for approval is 73.
287 227 -
200
400
Q1-FY15 Q1-FY16
USA
Rs.
cr.
$48
$36
EU Operations UK Operations
• 1 New filing done and 1 New product launched in
Q1FY16.
• UK operation Grows by 55% (grows by 59% £ terms) in
Q1FY16.
Investor Presentation August 2015 15
Ireland Operations
• Ireland Declines by 11% (growth of 4% in € terms) in
Q1FY16.
237 368 120
170
220
270
320
370
420
Q1-FY15 Q1-FY16
UK
Rs.
cr.
£ 23
£ 37
44 39 36
37
38
39
40
41
42
43
44
Q1-FY15 Q1-FY16
Ireland
Rs.
cr.
€ 5
€ 6
India & Emerging Markets • India Business Grows by 27% for Q1FY16.
• 24 new products in Q1FY16 launched in
India.
• Emerging Market operations grew by
47% in Q1FY16.
Investor Presentation August 2015 16
295 India
375 India
66 EM
97 EM
0
100
200
300
400
500
Q1FY15 Q1FY16
India & Emerging Markets (EM)
Rs.
cr.
Investor Presentation August 2015 17
For investor updates and communication please visit www.wockhardt.com
For Information please contact Arun Khatanhar Tel.: +91 22 71596228 [email protected]
